Zim Laboratories Limited has informed the Exchange about Grant of Marketing Authorisation

Zim Laboratories has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its migraine drug Rizatriptan Benzoate in an orally disintegrating film (ODF) form. The approval was secured through its Australian subsidiary ZIMTAS PTY LTD and marks the company's first product approval in Australia. Rizatriptan is used for acute treatment of migraine attacks in adults, and the ODF format allows intake without water — useful for patients with nausea or vomiting. The company sees this as a stepping stone for further regulatory filings across the Asia-Pacific region and validation of its proprietary thin-film drug delivery platform.